Journal Watch · Journal of Controlled Release · 2026

Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment.

Acquisition of knowledge of nanomedicine-based reprogramming of the TIME holds great potential to advance precision immunotherapy for CRC toward clinical translation.

Wu Y, Su Y, Wei Y et al.Journal of Controlled Release3 min readPharma relevance 95/100

DOI: 10.1016/j.jconrel.2026.114915PMID: 41967812Study type: review / perspective

TL;DR

Acquisition of knowledge of nanomedicine-based reprogramming of the TIME holds great potential to advance precision immunotherapy for CRC toward clinical translation.

Key findings

  • Based on the characteristic features of the TIME in CRC, this review summarizes recent advances in emerging preclinical nanomedicine-based strategies for TIME regulation in CRC treatment.
  • Furthermore, it provides perspectives on the challenges and opportunities of nanomedicines in modulating the TIME of CRC.
  • Acquisition of knowledge of nanomedicine-based reprogramming of the TIME holds great potential to advance precision immunotherapy for CRC toward clinical translation.

What they did

The complex tumor immune microenvironment (TIME), shaped by long-term interactions between cancer cells and microenvironmental components, is a key factor contributing to the poor response of most CRC patients to immunotherapy. With a deeper understanding of the TIME, nanomedicines have emerged as an effective strategy to remodel the TIME and achieve synergistic anti-tumor effects through targeted delivery of immunotherapeutic agents or multimodal combination therapeutic drugs.

Full abstract (original)

Background: Colorectal cancer (CRC), a malignant tumor with high incidence and mortality rates, poses a significant threat to human health. Although immunotherapeutic strategies such as immune checkpoint inhibitors (ICIs) have shown promising progress, limited efficacy, autoimmune side effects, systemic toxicity, and drug resistance remain major challenges in CRC immunotherapy.

What they did: The complex tumor immune microenvironment (TIME), shaped by long-term interactions between cancer cells and microenvironmental components, is a key factor contributing to the poor response of most CRC patients to immunotherapy. With a deeper understanding of the TIME, nanomedicines have emerged as an effective strategy to remodel the TIME and achieve synergistic anti-tumor effects through targeted delivery of immunotherapeutic agents or multimodal combination therapeutic drugs.

Results & conclusions: Based on the characteristic features of the TIME in CRC, this review summarizes recent advances in emerging preclinical nanomedicine-based strategies for TIME regulation in CRC treatment. Furthermore, it provides perspectives on the challenges and opportunities of nanomedicines in modulating the TIME of CRC. Acquisition of knowledge of nanomedicine-based reprogramming of the TIME holds great potential to advance precision immunotherapy for CRC toward clinical translation.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114915 · PubMed 41967812.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

Acquisition of knowledge of nanomedicine-based reprogramming of the TIME holds great potential to advance precision immunotherapy for CRC toward clinical translation.

What type of study is this?

It is a review / perspective, published in Journal of Controlled Release in 2026. The complex tumor immune microenvironment (TIME), shaped by long-term interactions between cancer cells and microenvironmental components, is a key factor contributing to the poor response of most CRC patients to immunotherapy.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.114915. PubMed ID: 41967812. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wu Y, Su Y, Wei Y et al.. Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.114915.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/nanomedicine-for-colorectal-cancer-therapy-by-remodeling-the-immune-micr-114915/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides